$1.38 Billion is the total value of Flagship Pioneering Inc.'s 18 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| FHTX | Foghorn Therapeutics Inc | $63,370,600 | -29.0% | 12,674,120 | 0.0% | 4.60% | +15.5% | |
| Omega Therapeutics Inc | $62,834,996 | -61.6% | 29,225,579 | 0.0% | 4.56% | -37.6% | ||
| MCRB | Seres Therapeutics Inc | $55,018,567 | -50.3% | 23,117,045 | 0.0% | 3.99% | -19.2% | |
| DNLI | Denali Therapeutics Inc | $54,049,940 | -30.1% | 2,619,968 | 0.0% | 3.92% | +13.7% | |
| Syros Pharmaceuticals Inc | $3,925,700 | +25.4% | 993,848 | 0.0% | 0.28% | +103.6% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Flagship Ventures Fund V General Partner LLC #1
- Flagship Ventures Fund IV General Partner LLC #2
- Noubar Afeyan #3
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| SERES THERAPEUTICS INC | 29 | Q3 2023 | 68.0% |
| DENALI THERAPEUTICS INC | 24 | Q3 2023 | 50.9% |
| SYROS PHARMACEUTICALS INC | 24 | Q2 2022 | 27.3% |
| MODERNA INC | 20 | Q3 2023 | 76.9% |
| EVELO BIOSCIENCES INC | 20 | Q1 2023 | 41.2% |
| RUBIUS THERAPEUTICS INC | 18 | Q4 2022 | 60.7% |
| Axcella Health Inc | 17 | Q2 2023 | 3.5% |
| KALEIDO BIOSCIENCES INC | 13 | Q1 2022 | 9.5% |
| Foghorn Therapeutics Inc | 12 | Q3 2023 | 6.5% |
| Sana Biotechnology Inc | 11 | Q3 2023 | 18.4% |
View Flagship Pioneering Inc.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 4 | 2023-09-15 |
| 4 | 2023-08-15 |
| 13F-HR | 2023-08-14 |
| 4 | 2023-07-13 |
| 13F-HR | 2023-05-15 |
| 4 | 2023-02-27 |
| 13F-HR | 2023-02-14 |
View Flagship Pioneering Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.